Navigation Links
Vantia Therapeutics' Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
Date:2/2/2010

SOUTHAMPTON, England, February 2 /PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia. The study is a randomised, double-blind, placebo-controlled study and is expected to recruit approximately 120 male patients at 20 centres in the US. The study will primarily assess number of nocturnal voids per night. Secondary endpoints include quality of life and sleep duration measures.

Nocturia (defined as waking to urinate at night thereby significantly disturbing sleep) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom in men with benign prostatic hypertrophy (BPH) and affects at least 70% of BPH patients. There are currently significant limitations in the treatment for nocturia and it represents a potential market estimated at more than US$1 billion.

In June last year, Vantia Therapeutics announced positive results from its Phase IIa trial of VA106483. The trial showed that oral VA106483 produced a predictable antidiuretic effect in elderly subjects, as determined by increased osmolality and decreased urine output. The study also showed that VA106483 was generally well tolerated in an elderly patient population.

VA106483 is a novel small molecule drug candidate that exerts its effect directly in the kidney by binding to vasopressin (V2) receptors, which regulate water excretion. It was discovered by scientists at Vantia Therapeutics from its extensive drug candidate library.

Dr Hilary McElwaine-Johnn, CMO of Vantia Therapeutics, said "Nocturia is a common condition, the prevalence of which increases markedly in older people. It is disruptive to sleep and can have a significant impact on the quality of life of patients. Our research suggests that only a very small percentage of patients with this symptom receive any kind of treatment. We are very pleased therefore to be starting this larger clinical study with VA106483 based on the encouraging results seen in earlier clinical studies."

Notes to Editors:

About Vantia Therapeutics

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research Ltd's small molecule R&D, it has two clinical phase products, VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation. The company's investors include MVM Life Science Partners, SV Life Sciences and Novo A/S. Vantia Therapeutics Ltd is situated on Southampton Science Park, UK, where it occupies 10,000 sq ft of chemistry and biology facilities. For further information, please go to http://www.vantia.com.

About nocturia

Nocturia (defined as waking to void at night) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients complaining of nocturia. Whilst some symptoms of BPH are successfully addressed by the standard BPH therapies of alpha blockers and 5-alpha reductase inhibitors, nocturia remains inadequately treated. With estimates putting the number of BPH/nocturia sufferers at 55 million in the seven largest markets world wide, and only 10% of these believed to be receiving any kind of treatment, it is a clear area of unmet medical need estimated to be worth in excess of $500m. The hormone vasopressin is involved in the regulation of the body's water content and as a vasopressin agonist VA106483 has been shown to act as an anti-diuretic.


    Contact details:

    Vantia Therapeutics
    Andy Crockett, VP Business Development +44(0)238-076-3456,
    +44(0)787-255-9676 info@vantia.com

    Citigate Dewe Rogerson
    Chris Gardner, Mark Swallow, Helena Galilee +44(0)207-638-9571
    vantia@citigatedr.co.uk

SOURCE Vantia Therapeutics


'/>"/>
SOURCE Vantia Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
2. Vantia Therapeutics Pipeline Continues to Mature
3. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
4. Pepscan Therapeutics Strengthens Management Team
5. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
6. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
7. Echo Therapeutics Announces Major Milestone: The Completion of Product Development Work of its Revolutionary, Patented Prelude(TM) SkinPrep System
8. Advanced Cardiac Therapeutics Completes $5 Million Financing
9. Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference
10. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
11. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):